Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide in high‑risk non‑metastatic castration‑resistant prostate cancer
jRCT2080223045Phase 3Completed
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Darolutamide with Placebo / control (2 arms). Primary endpoint: Metastasis-free survival. Started Dec 2015; status: completed.
02
Drugs
darolutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCT2080223045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223045.